Section 4 of 6
Clinical evidence
467 evidence topics · 59 sources
Study summaries
Launch-HTN
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Main objective in the EU Clinical Trials Information System record
Objective stated in the publication
“To evaluate the efficacy and safety of lorundrostat for lowering blood pressure (BP) when added to a prescribed regimen of 2 to 5 antihypertensive medications in adults with uncontrolled hypertension and treatment-resistant hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The phase 3 Launch-HTN randomized clinical trial evaluated the efficacy, tolerability, and safety of lorundrostat in participants with uncontrolled hypertension, including those with apparent treatment-resistant hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2023-11-22” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2024-12-10” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-01-24” (opens the source at this quote in a new tab)
“First Posted 2023-12-01” (opens the source at this quote in a new tab)
“Last Update Posted 2026-05-01” (opens the source at this quote in a new tab)
“No longer looking for participants” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Study locations by country in the ClinicalTrials.gov record
Enrollment period, sites, and countries reported in the publication
“In this phase 3, randomized clinical trial, adults with uncontrolled hypertension, including those with treatment-resistant hypertension, were enrolled between November 2023 and September 2024 at 159 clinic sites across 13 countries. The last date of follow-up was January 24, 2025.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current double-blind, placebo-controlled randomized clinical trial screened participants at 159 sites across 13 countries. The participants were recruited by investigators from primary and secondary care clinics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EU member states, trial start, and end of trial in the EU Clinical Trials Information System record
Trial and recruitment dates by EU member state
| Member state | Status | Decision date | Trial start date | Trial end | Recruitment start | Recruitment end |
|---|---|---|---|---|---|---|
| Spain | “Ended” | “08/04/2024” | “23/04/2024” | “03/01/2025” | “29/05/2024” | “18/10/2024” |
| Germany | “Ended” | “10/04/2024” | “18/04/2024” | “09/01/2025” | “28/05/2024” | “18/10/2024” |
| France | “Ended” | “10/04/2024” | “31/05/2024” | “02/01/2025” | “05/09/2024” | “18/10/2024” |
| Italy | “Ended” | “10/04/2024” | “07/05/2024” | “16/01/2025” | “04/06/2024” | “18/10/2024” |
| Netherlands | “Ended” | “11/04/2024” | “22/05/2024” | “06/01/2025” | “26/08/2024” | “18/10/2024” |
| Poland | “Ended” | “12/04/2024” | “08/05/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |
| Bulgaria | “Ended” | “15/04/2024” | “17/04/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |
| Romania | “Ended” | “15/04/2024” | “27/05/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |
Study design
Design details in the ClinicalTrials.gov record
“Primary Purpose : Treatment” (opens the source at this quote in a new tab)
“Allocation : Randomized” (opens the source at this quote in a new tab)
“Interventional Model : Parallel Assignment” (opens the source at this quote in a new tab)
“Masking : Double” (opens the source at this quote in a new tab)
“Other Study ID Numbers MLS-101-301” (opens the source at this quote in a new tab)
“Phase Phase 3” (opens the source at this quote in a new tab)
Study periods in the ClinicalTrials.gov detailed description
Trial phase in the EU Clinical Trials Information System record
Trial phases, randomization, and stratification in the publication
“The trial was composed of 3 phases: screening, a 2-week single-blind placebo run-in, and a 12-week randomized, double-blind treatment phase (eFigure 1 in Supplement 1). Upon completion, participants had the option to enroll in an open-label extension trial of lorundrostat or participate in a 2-week safety follow-up. Participants continued taking their prescribed antihypertensive medications for the duration of the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Random permuted block sizes of 4 and 8 were used for randomization, which was stratified by geography (Australia, Canada, Europe, and the US). The randomization sequence was implemented using the Rave RTSM (a randomization and trial supply management system manufactured by Medidata).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding and oversight
“The placebo tablets were identical in color, shape, and packaging to the tablets containing lorundrostat. Participants took 2 tablets at each dosing to ensure blinding of dose escalation after week 6. The treatment assignment was masked to participants, investigators, individuals assessing the outcomes, and individuals analyzing the data until the final database lock.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An independent, unblinded data and safety monitoring committee assessed the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure measurement protocol
“Unattended, automated office BP was assessed at screening, at randomization (baseline), at weeks 2, 4, 6, 8, and 12 during the double-blind treatment phase, and at an optional safety follow-up visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each site was provided with an identical automated oscillometric BP device (MicroLife WatchBP Office AFIB), training, and an instruction manual for collecting BP measurements. All BP was measured with an appropriately sized cuff on the same arm of the participant throughout the trial at approximately the same time, preferably in the morning. After an initial 5-minute rest phase, 5 unattended seated measurements were performed with a 1-minute break between each reading; the last 4 measurements were used to calculate the mean and reduce within-participant variance in measuring BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A standing measurement followed the seated measurements to monitor for orthostatic hypotension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Design described by the company: background medications continued
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Age range in the EU Clinical Trials Information System record
Trial population and prohibited medications in the publication
“Males or females aged 18 years or older with an unattended automated office systolic BP of 135 to 180 mm Hg and diastolic BP of 65 to 110 mm Hg or an isolated automated office diastolic BP of 90 to 110 mm Hg while taking stable doses of 2 to 5 prescribed antihypertensive medications (including a thiazide or thiazide-like diuretic) were eligible for inclusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The key exclusion criteria were an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m2, a serum potassium level of greater than 5.0 mmol/L at screening or greater than 4.8 mmol/L at randomization, and a serum sodium level of less than 135 mmol/L at screening. The use of epithelial sodium channel inhibitors, MRAs, and potassium-sparing diuretics was prohibited 4 weeks prior to screening to trial completion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Additional inclusion criteria in the supplementary eMethods
Additional exclusion criteria in the supplementary eMethods
Treatment
Arms and interventions in the ClinicalTrials.gov record
Randomization ratio and criteria for escalation to 100 mg at week 6
“Upon confirmation of eligibility for randomization after the placebo run-in phase, participants were randomly assigned in a 1:2:1 ratio to receive 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks (n = 270) if they met prespecified criteria at week 6 (the prespecified criteria were office systolic BP ≥130 mm Hg, serum potassium level ≤4.8 mmol/L, serum sodium level ≥135 mmol/L, eGFR >45 mL/min/1.73 m2, and <25% reduction in eGFR from baseline), 50 mg of lorundrostat once daily for 12 weeks (n = 541), or placebo once daily for 12 weeks (n = 272).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The participants in the lorundrostat group who did not meet all of the prespecified criteria at week 6 continued to receive the 50-mg dose for the remaining 6 weeks of double-blind treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration, dose modification, and adherence reminders
“Lorundrostat or matching placebo tablets were administered orally once daily at approximately the same time each morning. Participants were reminded about taking their trial medication using a smartphone application (AiCure).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The trial medication dose could be reduced, temporarily withheld, or permanently discontinued for safety concerns at the discretion of the investigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Registered primary and secondary outcome measures in the ClinicalTrials.gov record
Primary outcome and key secondary outcomes in the publication
“The primary efficacy outcome was the change in office systolic BP at week 6 for participants randomized to 50 mg of lorundrostat vs placebo. The key secondary outcomes controlled for multiplicity and included the proportion of participants with an office systolic BP of less than 130 mm Hg at week 6; change in office systolic BP at week 6 in participants taking 2 prescribed antihypertensive medications or taking 3 or more prescribed antihypertensive medications; change in office systolic BP from baseline by continuous body mass index (BMI; calculated as weight in kilograms divided by height in meters squared); change in office systolic BP at week 12; and change in office systolic BP from baseline at week 12 in participants who met prespecified criteria and were escalated from 50 mg to 100 mg of lorundrostat after week 6 (eTable 1 in Supplement 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint at week 6 pooled across both lorundrostat groups
Choice of unattended automated office measurement stated by the investigators
“Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current trial aimed to minimize the variable nature of office BP measurement by (1) obtaining measurements prior to the intake of morning medications, (2) using unattended BP measurements to limit the white-coat effect, and (3) using the mean of repeated BP measurements to reduce intraindividual variability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Automated office blood pressure in the American Heart Association scientific statement
“AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unattended AOBP has been associated with a lower prevalence of white-coat effect compared with office BP measured through auscultation and reduces the possibility of human error in BP measurement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Difference between unattended and attended automated office measurements
“The unattended systolic BP and diastolic BP were −2.7 (−4.7 to −0.6) and −0.9 (−1.8 to −0.1) mm Hg lower than attended BPs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Standardized unattended AOBP measurements result in slightly lower readings than attended AOBP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure as the basis of benefit in FDA labeling guidance
Blood pressure in the FDA table of surrogate endpoints
| Disease or use | Patient population | Surrogate endpoint | Type of approval appropriate for |
|---|---|---|---|
| “Hypertension” | “Patients with hypertension” | “Blood pressure” | “Traditional” |
Studies on a background of multiple antihypertensive drugs in FDA draft guidance
Cardiovascular risk reduction per 5 mm Hg lower systolic blood pressure
“In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint: office systolic blood pressure below 130 mm Hg
Key secondary endpoint: participants taking 3 or more antihypertensive medications
Key secondary endpoint: obesity and aldosterone dysregulation
“There is increasing awareness that primary aldosteronism and the secondary causes of increased aldosterone production, including obesity and aldosterone breakthrough, contribute significantly to elevated BP and a lack of BP control among patients with hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiplicity hierarchy of the primary and secondary hypotheses
Prespecified adverse events of special interest
“Safety was assessed as the proportion of participants having received at least 1 dose of trial medication experiencing any treatment-emergent adverse events. Prespecified adverse events of special interest included dose reduction, interruption, or discontinuation due to hyperkalemia, hyponatremia, and reduction in kidney function (decline in eGFR) as well as treatment discontinuation due to glucocorticoid deficiency, symptomatic hypotension, severely elevated BP, or overdose of trial drug or prescribed antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation and power
“The sample size of 1000 participants randomized to 1 of 3 treatment groups in a 1:2:1 ratio had 95% power to detect a difference of 3.7 mm Hg in office systolic BP between lorundrostat (n = 750) and placebo (n = 250) at a 1-sided α level of .025, assuming a common SD of 14 mm Hg for change in office systolic BP. This sample size allowed robust safety monitoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Actual enrollment in the ClinicalTrials.gov record
Participants randomized and dosed by group
“Of the 1083 participants randomized, 1078 received at least 1 dose of 50 mg/d of lorundrostat for 6 weeks with the potential dose increase to 100 mg/d (n = 270), 50 mg/d of lorundrostat for 12 weeks (n = 538), or daily placebo for 12 weeks (n = 270) (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants in the primary analysis
Participants in the chronic kidney disease analysis
Description of analysis sets
Intention-to-treat and safety populations
“Included participants who received at least 1 dose of trial drug according to treatment assignment at randomization.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Included participants who received at least 1 dose of trial drug according to the actual treatment they received.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participant Demographics and Characteristics at Randomization (Baseline) in the Intention-to-Treat Population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary estimand and analysis model
“The primary estimand followed the treatment policy approach by using all observed efficacy data regardless of possible treatment discontinuation. The primary outcome was analyzed on 1000 multiple imputed data using analysis of covariance with categorical factors for treatment, geographic region or country (randomization stratification factor), and treatment interaction with geographic region or country and using baseline office systolic BP as a covariate. Canada and the US were merged into 1 geographic stratum because only 3 participants were randomized in Canada.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The secondary outcomes were analyzed on multiple imputed data using the analysis methods described in eTable 2 in Supplement 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intercurrent events and handling of missing data
Analysis of the obesity and within-participant secondary hypotheses
Sensitivity analyses of the primary endpoint
Population of the responder analysis
Definition of chronic kidney disease in the subgroup analysis
Results
Participant disposition
Screening, run-in, randomization, and dosing
“Between November 24, 2023, and September 16, 2024, 3161 participants were screened, 1575 entered the placebo-run in phase, and 1083 were randomized to the double-blind treatment phase” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 1083 participants randomized, 1078 received at least 1 dose of 50 mg/d of lorundrostat for 6 weeks with the potential dose increase to 100 mg/d (n = 270), 50 mg/d of lorundrostat for 12 weeks (n = 538), or daily placebo for 12 weeks (n = 270) (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Most frequent reasons for exclusion
“The most frequent reasons were current use of treatment (or anticipated treatment) with any of the prohibited medications described in the trial protocol within a specified time frame (n = 15); had a condition that would preclude participation in the study (based on the opinion of the investigator) (n = 14); and had current, known, or presumed orthostatic hypotension (n = 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intercurrent events and missing data
Enrollment of lorundrostat-treated participants in the open-label extension
Baseline characteristics
Demographic summary of the randomized population
“Of the 1083 participants, the mean age was 61.6 years (SD, 10.3 years), 508 (46.9%) were female, 311 (28.7%) were Black or African American, 733 (67.7%) were White, and 685 (63.3%) had a body mass index of 30 or greater (obesity). At randomization, 432 participants (39.9%) were taking 2 prescribed antihypertensive medications and 651 (60.1%) were taking 3 or more.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The randomized groups were comparable for the baseline demographic and clinical characteristics (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics by randomized group
Baseline characteristics of the responder analysis population
Baseline characteristics of participants with chronic kidney disease
Efficacy results
Primary endpoint: change in office systolic blood pressure at week 6
“The least-squares mean change in office systolic BP at week 6 was −16.9 mm Hg (95% CI, −19.0 to −14.9 mm Hg) for the pooled 50 mg of lorundrostat group vs −7.9 mm Hg (95% CI, −11.5 to −4.2 mm Hg) for the placebo group (least-squares between-group mean difference, −9.1 mm Hg [95% CI, −13.3 to −4.9 mm Hg], P < .001; Table 2 and Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary, secondary, and prespecified exploratory blood pressure outcomes
Observed proportion with office systolic blood pressure below 130 mm Hg at week 6
Key secondary endpoints at week 6
“An office systolic BP of less than 130 mm Hg at week 6 was achieved by 44.1% of participants in the pooled 50 mg of lorundrostat group vs 24.1% of participants in the placebo group (odds ratio, 3.4 [95% CI, 1.5 to 7.8]; P = .003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −8.8 mm Hg (97.5% CI, −14.8 to −2.9 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 2 prescribed antihypertensive medications. Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −9.0 mm Hg (97.5% CI, −14.0 to −4.1 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 3 or more antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A comparable reduction in office systolic BP was observed across the continuum of BMI represented in the trial; 91.6% of participants had a BMI of 25 or greater.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoints at week 12 with escalation to 100 mg
“Compared with placebo, the least-squares mean change in office systolic BP at week 12 was −8.4 mm Hg (95% CI, −13.6 to −3.2 mm Hg; P = .002) for participants randomized to 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks. Compared with placebo, the least-squares mean change in office systolic BP at week 12 was −10.2 mm Hg (97.5% CI, −14.3 to −6.1 mm Hg; P < .001) for the 92 participants who escalated from 50 mg of lorundrostat to 100 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing the 50-mg/d dose of lorundrostat to 100 mg/d provided no additional benefit to participants who did not reach the goal BP using the 50-mg/d dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroup consistency of the primary endpoint
Prespecified exploratory endpoints: diastolic blood pressure at week 6 and systolic blood pressure at week 12
Sensitivity analyses of the primary endpoint
| Analysis | Lorundrostat LS mean (SE) | Placebo LS mean (SE) | LS mean difference (SE) | 95% CI of LS mean difference | P value |
|---|---|---|---|---|---|
| Sensitivity analysis 1: intercurrent events treated as missing at random (lorundrostat n = 808; placebo n = 270) | “-16.9 (1.1)” | “-7.9 (1.9)” | “-9.1 (2.1)” | “-13.3 to -4.9” | “<0.001” |
| Sensitivity analysis 2: all missing data treated as missing not at random (lorundrostat n = 808; placebo n = 270) | “-16.5 (1.1)” | “-7.9 (1.9)” | “-8.6 (2.2)” | “-12.2 to -4.4” | “<0.001” |
| Sensitivity analysis 4: observed data only (lorundrostat n = 755; placebo n = 257) | “-17.0 (1.1)” | “-7.9 (1.9)” | “-9.1 (2.1)” | “-13.3 to -4.9” | “<0.001” |
Tipping point sensitivity analysis
Week 6 and week 12 results in the topline announcement, March 2025
Week 12 placebo-adjusted result in the annual report
Responder analysis: office systolic blood pressure below 130 mm Hg and reductions of 5, 10, and 20 mm Hg at week 12
Participants with and without chronic kidney disease: systolic blood pressure and albuminuria at week 12
Participants with and without chronic kidney disease: results by stage
| CKD stage (placebo N; lorundrostat 50 mg N) | Placebo AOSBP LSM (95% CI) change at week 12 | Lorundrostat 50 mg AOSBP LSM (95% CI) change at week 12 | Placebo adjusted (95% CI) | Placebo week 12 % with AOSBP <130 mmHg | Lorundrostat 50 mg week 12 % with AOSBP <130 mmHg |
|---|---|---|---|---|---|
| No CKD (202; 406) | “-7.2 (-11.3, -3.2)” | “-19.4 (-22.2, -16.6)” | “-12.2 (-17.1, -7.3)” | “22.1” | “48.0” |
| Stage 1 (30; 58) | “-8.9 (-15.4, -2.3)” | “-19.5 (-24.1, -14.9)” | “-10.6 (-18.6, -2.6)” | “18.4” | “50.6” |
| Stage 2 (25; 31) | “-9.1 (-15.9, -2.4)” | “-16.7 (-22.6, -10.8)” | “-7.6 (-16.5, 1.4)” | “12.0” | “28.4” |
| Stage 3 (10; 38) | “-8.5 (-18.1, 1.1)” | “-18.5 (-24.1, -13.0)” | “-10.1 (-21.1, 1.0)” | “30.0” | “47.0” |
Participants with chronic kidney disease: P values and albuminuria population
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events by randomized group
Overall adverse events, serious adverse events, and deaths
“Treatment-emergent adverse events were experienced by 49.9% of participants (538/1078) and were mostly mild or moderate in severity (Table 3). Serious adverse events occurred in 22 participants and included 1 event that was considered to be related to treatment. One participant in the placebo group died after week 6 (unrelated to treatment).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definitions used in the adverse event table
“Defined as systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mm Hg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Trial drug had to be modified due to the adverse event (dose reduction, interruption, or discontinuation).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Confirmed by adrenocorticotropic hormone (cosyntropin or regional equivalent) stimulation test; trial drug was discontinued.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum potassium above 6.0 mmol/L
“A serum potassium level of greater than 6.0 mmol/L occurred in 4 participants (1.5%) randomized to 50 mg of lorundrostat group with possible dose escalation to 100 mg, in 6 participants (1.1%) randomized to 50 mg of lorundrostat, and in 2 participants (0.7%) randomized to placebo (eTable 4 in Supplement 1). The mean serum potassium level increased in the 2 lorundrostat groups but remained within normal range (eFigure 5 in Supplement 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum sodium and potassium thresholds by randomized group
| Level, n (%) | Lorundrostat 50 to 100 mg daily (n=270) | Lorundrostat 50 mg (n=538) | Placebo (n=270) |
|---|---|---|---|
| Serum sodium <132 mmol/L | “22 (8.1)” | “38 (7.1)” | “13 (4.8)” |
| Serum sodium <130 mmol/L | “11 (4.1)” | “14 (2.6)” | “4 (1.5)” |
| Serum sodium <125 mmol/L | “4 (1.5)” | “4 (0.7)” | “1 (0.4)” |
| Serum potassium 5.6 to 6.0 mmol/L, single value | “29 (10.7)” | “38 (7.1)” | “3 (1.1)” |
| Serum potassium 6.1 to 6.5 mmol/L, single value | “2 (0.7)” | “5 (0.9)” | “1 (0.4)” |
| Serum potassium >6.5 mmol/L, single value | “2 (0.7)” | “1 (0.2)” | “1 (0.4)” |
| Serum potassium 5.6 to 6.0 mmol/L, confirmed | “24 (8.9)” | “31 (5.8)” | “2 (0.7)” |
| Serum potassium 6.1 to 6.5 mmol/L, confirmed | “2 (0.7)” | “3 (0.6)” | “1 (0.4)” |
| Serum potassium >6.5 mmol/L, confirmed | “1 (0.4)” | “0” | “0” |
Counting rules for the sodium and potassium table
Confirmed hyperkalemia reported by the company
Kidney function: creatinine-based and cystatin C-based eGFR
“Creatinine-based eGFR decreased by 9.3% from baseline to week 12 in the 2 lorundrostat groups and increased by 0.4% in the placebo group. Using the cystatin-C–based eGFR formula, eGFR decreased by 5.2% in the 50 mg of lorundrostat group with possible escalation to 100 mg, decreased by 4.1% in the 50 mg of lorundrostat group, and increased by 3.4% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The observed decline in eGFR (assessed using the cystatin C–based eGFR formula to correct for falsely elevated creatinine due to competition between lorundrostat and creatinine for MATE [multidrug and toxin extrusion] 1–dependent transport) after initiation of lorundrostat was expected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cortisol and glucocorticoid insufficiency
“At week 12, the geometric mean for serum cortisol increased by 4.2% from baseline in the 50 mg of lorundrostat group with possible escalation to 100 mg, increased by 5.0% in the 50 mg of lorundrostat group, and decreased by 2.0% in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment-emergent adverse event of glucocorticoid insufficiency was reported in 0 participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, in 3 participants (0.56%) in the 50 mg of lorundrostat group, and in 5 participants (1.9%) in the placebo group. No participants treated with lorundrostat experienced a glucocorticoid deficiency (confirmed by stimulation testing; Table 3). There were no reports of hyperadrenocorticism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment discontinuation due to hyperkalemia, hyponatremia, or reduced kidney function
“Among participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, treatment discontinuation occurred in 1 (0.37%) due to hyperkalemia, in 1 (0.37%) due to hyponatremia, and in 0 due to reduction in kidney function (decline in eGFR). Among participants in the 50 mg of lorundrostat group, treatment discontinuation occurred in 2 (0.37%) due to hyperkalemia, in 2 (0.37%) due to hyponatremia, and in 3 (0.56%) due to reduction in kidney function (decline in eGFR). Among participants in the placebo group, there were no treatment discontinuations due to hyperkalemia, hyponatremia, or reduction in kidney function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse events reported in the topline announcement
Confirmed hyperkalemia and symptomatic hypotension in the responder analysis
Participants with chronic kidney disease: potassium and cystatin C-based eGFR
Study limitations
Summary: study limitations
Launch-HTN randomized 1,083 participants and compared lorundrostat with placebo for 12 weeks, a duration the investigators describe as “consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration”. Longer-term data come from the open-label extension, which enrolled 632 of the 808 participants who received lorundrostat in Launch-HTN. The trial had no active comparator. The primary endpoint, unattended automated office systolic blood pressure at week 6, was chosen “to reflect usual clinical practice”; the investigators note that ambulatory measurement “is the gold standard for assessment of BP”. FDA guidance attributes the cardiovascular benefits of antihypertensive drugs largely to the decrease in blood pressure, and the trial did not measure cardiovascular outcomes.
In the escalation group, 92 of 270 participants (34.1%) met the week 6 criteria and received 100 mg, and the investigators conclude that the higher dose “provided no additional benefit” to participants who had not reached goal on 50 mg; the week 12 placebo-adjusted difference in the escalation group (−8.4 mm Hg) was smaller than in the 50 mg group (−11.6 mm Hg). Two week 12 values are reported for the 50 mg group: −11.6 mm Hg in the publication and 11.7 mm Hg in the March 2025 topline announcement.
Eligibility excluded people with eGFR below 45 mL/min/1.73 m2, serum potassium above 5.0 mmol/L at screening or above 4.8 mmol/L at randomization, serum sodium below 135 mmol/L, or heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months, and prohibited mineralocorticoid receptor antagonists, epithelial sodium channel inhibitors, and potassium-sparing diuretics. Of the 1,083 participants, 685 (63.3%) had obesity and 432 (39.9%) were taking 2 antihypertensive medications, so the population includes people who would not meet the 2025 AHA/ACC definition of resistant hypertension. Three participants were randomized in Canada. The publication reports 159 sites in 13 countries, while the registry lists 184 locations. Hyperkalemia rates depend on the definition: a single serum potassium above 6.0 mmol/L occurred in 1.5% and 1.1% of the two lorundrostat groups and 0.7% of the placebo group, while the company reports confirmed hyperkalemia of 1.1% and 0.6%, respectively. The responder analysis is described as a “secondary analysis” and the chronic kidney disease analysis as a “Post hoc analysis”; both are published as conference abstracts. No health-related quality of life or patient-reported outcome was reported. The sponsor's chief medical officer and lead statistician are listed among the sponsor leadership of the trial and are authors of the publication.
Limitations stated by the investigators
“This trial has limitations. First, the efficacy and safety of lorundrostat compared with placebo was evaluated for only 12 weeks. This is consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration. However, eligible participants had the option to continue in an open-label extension trial (NCT05968430), which intends to provide safety and efficacy information relevant to longer-term use of lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice. Importantly, the phase 2 Advance-HTN trial18 of lorundrostat used 24-hour ambulatory BP measurements and, compared with placebo, demonstrated similar patterns of BP lowering after 12 weeks of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Third, the current trial compared the efficacy of lorundrostat vs placebo, but the trial did not include an active comparator.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-office measurement and cardiovascular risk prediction
Advance-HTN
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2023-03-13” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-01-15” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-01-15” (opens the source at this quote in a new tab)
“First Posted 2023-03-15” (opens the source at this quote in a new tab)
“Last Update Posted 2026-01-20” (opens the source at this quote in a new tab)
Number and country of locations in the ClinicalTrials.gov record
Number of sites stated in the trial presentation
Topline results announced in March 2025
Presentation at the American College of Cardiology Scientific Session in March 2025
Publication in April 2025
Study design
Official title and design in the ClinicalTrials.gov record
Design features stated in the trial presentation
“Multicenter (103 sites in the United States)” (opens the source at this quote in a new tab)
“Prospective” (opens the source at this quote in a new tab)
“Randomized” (opens the source at this quote in a new tab)
“Double-blind” (opens the source at this quote in a new tab)
“Placebo-controlled” (opens the source at this quote in a new tab)
“Parallel group” (opens the source at this quote in a new tab)
“Phase 2b trial” (opens the source at this quote in a new tab)
Trial periods and their durations in the trial presentation
| Period | Quoted record |
|---|---|
| Screening | “2 weeks” |
| Single-blind run-in on the standardized regimen | “3 weeks” |
| Randomized double-blind treatment | “12 weeks” |
| After the end of treatment | “Open-label extension”; “2-week end of study visit”; “4-week washout” |
Design stated in the publication abstract
“In this multicenter, double-blind, randomized, placebo-controlled trial, we assigned participants who were receiving two to five antihypertensive medications and had a blood-pressure measurement of 140/90 mm Hg or higher obtained during an office visit to undergo a standardized antihypertensive regimen for 3 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Role in the pivotal program stated by the company
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Age, sex, and healthy volunteers in the ClinicalTrials.gov record
Blood pressure, medication, and laboratory thresholds in the trial presentation
| Criterion | Quoted record |
|---|---|
| Background antihypertensive medications at screening | “2 - 5 BP medications” |
| Office blood pressure at screening | “SBP 140 to 180 mm Hg, or DBP 90 to 110 mm Hg” |
| 24-hour ambulatory blood pressure before randomization | “SBP 130 to 180 mm Hg, or DBP > 80 mm Hg” |
| Serum sodium | “Na+ ≥ 135” |
| Estimated glomerular filtration rate | “eGFR ≥ 45” |
Eligibility for randomization after the standardized regimen in the publication abstract
Treatment
Standardized antihypertensive regimen during the run-in
“Switch to standardized regimen:” (opens the source at this quote in a new tab)
“Indapamide 2.5 mg daily or HCTZ 25 mg daily” (opens the source at this quote in a new tab)
“Olmesartan 40 mg daily” (opens the source at this quote in a new tab)
“+/- Amlodipine 10 mg daily” (opens the source at this quote in a new tab)
Standardized regimen assigned by the number of prior medications
Randomized treatment arms in the ClinicalTrials.gov record
| Arm | Quoted record |
|---|---|
| Placebo comparator | “Placebo once daily for 12 weeks” |
| Experimental: Dose 1 | “lorundrostat Dose 1 once daily for 12 weeks” |
| Experimental: Dose 2 | “lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria” |
Doses and dose-adjustment rule in the publication abstract
“assigned to receive placebo, lorundrostat at a stable dose of 50 mg daily (the stable-dose group), or lorundrostat at a starting dose of 50 mg daily, with an increase to 100 mg daily if systolic blood pressure was 130 mm Hg or higher after 4 weeks (the dose-adjustment group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment duration and titration stated by the company
Study outcomes
Rationale for using change in 24-hour ambulatory systolic blood pressure as the primary endpoint
Registered primary outcome measure in the ClinicalTrials.gov record
Primary end point defined in the publication abstract
“The primary end point was the change in 24-hour average systolic blood pressure from baseline to week 12, assessed as the least-squares mean difference from placebo (the placebo-adjusted change) in each lorundrostat group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ambulatory blood pressure monitoring as the reference measurement, stated by the lead investigator
Ambulatory and clinic blood pressure as predictors of mortality
“Ambulatory blood pressure provides a more comprehensive assessment than clinic blood pressure, and has been reported to better predict health outcomes than clinic or home pressure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After adjustment for clinic blood pressure, 24-h blood pressure remained strongly associated with all-cause deaths (HR 1·43 [95% CI 1·37-1·49]), but the association between clinic blood pressure and all-cause death was attenuated when adjusted for 24-h blood pressure (1·04 [1·00-1·09]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ambulatory blood pressure, particularly night-time blood pressure, was more informative about the risk of all-cause death and cardiovascular death than clinic blood pressure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-office blood pressure in the 2025 AHA/ACC guideline
Blood pressure reduction as the basis of cardiovascular benefit
Same primary endpoint in a phase 3 trial of another aldosterone synthase inhibitor
“The primary endpoint was change in 24 h ambulatory SBP from baseline to week 12, assessed by analysis of covariance in patients administered at least one dose of study medication with valid ambulatory SBP measurement at baseline and week 12.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary end points in the trial presentation
Key secondary end point defined in the publication abstract
Registered secondary outcome measures in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Participants randomized and analyzed for efficacy in the trial presentation
Participants in the primary and key secondary analyses stated by the company
Planned sample size and statistical power
No evidence found.
Description of analysis sets
Comparisons for the primary and key secondary end points in the publication abstract
“assessed as the least-squares mean difference from placebo (the placebo-adjusted change) in each lorundrostat group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“assessed as the placebo-adjusted change in the combined lorundrostat groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Control of multiplicity for the key secondary end points
Within-participant analysis for participants escalated to 100 mg
Hyperkalemia confirmed by repeat testing in the safety analysis
Results
Participant disposition
Screening, run-in, and randomization in the trial presentation
“2617 patients assessed for eligibility” (opens the source at this quote in a new tab)
“1691 ineligible” (opens the source at this quote in a new tab)
“926 enrolled & started standardized regimen” (opens the source at this quote in a new tab)
“641 ineligible” (opens the source at this quote in a new tab)
“53% due to ABPM” (opens the source at this quote in a new tab)
“285 randomized” (opens the source at this quote in a new tab)
“94 included in the efficacy analysis” (opens the source at this quote in a new tab)
Randomization by treatment group in the publication abstract
Baseline characteristics
Participant characteristics by treatment group in the trial presentation
| Characteristic | Placebo | Lorundrostat 50 mg | Lorundrostat 50 to 100 mg |
|---|---|---|---|
| Age (years) | “59” | “61” | “61” |
| Women (%) | “35%” | “40%” | “44%” |
| Black or African-American (%) | “46%” | “53%” | “58%” |
| BMI (kg/m2) | “32” | “31” | “32” |
| eGFR (randomization) | “74” | “77” | “76” |
| Office BP (screening) | “155/91” | “153/88” | “152/89” |
| 24-hour ABPM (randomization) | “141/87” | “141/86” | “141/87” |
Obesity, sex, and race stated by the company
Efficacy results
Primary end point: change in 24-hour average systolic blood pressure at week 12
“After 12 weeks, the least-squares mean change in 24-hour average systolic blood pressure was -15.4 mm Hg in the stable-dose group, -13.9 mm Hg in the dose-adjustment group, and -7.4 mm Hg in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The placebo-adjusted change in blood pressure was -7.9 mm Hg (97.5% confidence interval [CI], -13.3 to -2.6) in the stable-dose group and -6.5 mm Hg (97.5% CI, -11.8 to -1.2) in the dose-adjustment group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary end point: placebo-adjusted changes with P values in the trial presentation
Key secondary end point: change in 24-hour average systolic blood pressure at week 4, combined lorundrostat groups
“The placebo-adjusted change in 24-hour average systolic blood pressure from baseline to week 4 in the combined lorundrostat groups was -5.3 mm Hg (95% CI, -8.4 to -2.3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Group | Least-squares mean change at week 4 (mm Hg) |
|---|---|
| Placebo | “-6.2” |
| Lorundrostat 50 mg (all) | “-11.5” |
| Placebo-adjusted difference | “Placebo-adjusted: -5.3 (-8.4 to -2.3) P < 0.001” |
Key secondary end point: 24-hour average systolic blood pressure below 125 mm Hg at week 4
| Group | Proportion with 24-hour average SBP <125 mm Hg at week 4 |
|---|---|
| Placebo | “18%” |
| Lorundrostat 50 mg (all) | “41%” |
| Odds ratio (95% CI) | “3.3 (1.4 to 7.8) P < 0.001” |
Key secondary end point: change at week 4 by number of background medications
| Background medications | Placebo n | Placebo change (mm Hg) | Lorundrostat n | Lorundrostat change (mm Hg) | Placebo-adjusted difference |
|---|---|---|---|---|---|
| 2 | “n = 60” | “-5.1” | “n = 117” | “-11.2” | “-6.1 (-10.8 to -1.4) P = 0.001” |
| 3 | “n = 34” | “-7.2” | “n = 71” | “-11.8” | “-4.6 (-10.6 to 1.5) P = 0.060” |
Key secondary end point: office systolic blood pressure at week 12 in participants escalated to 100 mg
Key secondary end point: relationship of body mass index to blood pressure reduction at week 4
Dose escalation compared with the stable 50 mg dose
Conclusion of the publication abstract
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events by treatment group in the trial presentation
| Adverse event | Placebo | Lorundrostat 50 mg | Lorundrostat 50 to 100 mg |
|---|---|---|---|
| Any serious AE | “2%” | “6%” | “8%” |
| Any study-drug related serious AE | “0” | “2%” | “1%” |
| Hypotension | “3%” | “9%” | “8%” |
| Hyponatremia | “6%” | “9%” | “11%” |
| Hyperkalemia (>6.0 mmol/L), single value | “0” | “5%” | “7%” |
| Hyperkalemia (>6.0 mmol/L), confirmed via per protocol repeat testing | “0” | “2%” | “3%” |
Hyperkalemia above 6.0 mmol per liter
“A potassium level above 6.0 mmol per liter occurred in 5 participants (5%) in the stable-dose group, 7 participants (7%) in the dose-adjustment group, and no participants in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hyperkalemia in Advance-HTN compared with Launch-HTN
Serum electrolytes and cortisol stated by the company
Study limitations
Summary
Advance-HTN was a 12-week phase 2 trial (the presentation calls it a “Phase 2b trial”) in 285 randomized participants at sites in the United States only (104 locations in the registry record; 103 sites in the presentation). Every participant was switched to a standardized regimen of a diuretic, olmesartan, and, for those previously on 3 to 5 drugs, amlodipine, so the results describe lorundrostat added to that regimen and may differ from its effect on top of usual background therapy; the presenters list the need for “additional data using office blood pressure on top of usual care” from Launch-HTN as a limitation. Of 926 participants who started the standardized regimen, 641 were ineligible for randomization (53% because of the ambulatory blood pressure criterion), which selects a population with confirmed uncontrolled hypertension on a standardized regimen.
The 50 to 100 mg dose-adjustment strategy produced a smaller placebo-adjusted reduction at week 12 (-6.5 mm Hg) than the stable 50 mg dose (-7.9 mm Hg), and 19 participants were escalated to 100 mg, so the trial gives limited information on the 100 mg dose. The week 4 subgroup on 3 background medications (71 lorundrostat and 34 placebo participants) had a placebo-adjusted difference of -4.6 mm Hg with a confidence interval that crossed zero (P = 0.060). The placebo group had a 24-hour systolic reduction of 7.4 mm Hg at week 12.
Single-value potassium above 6.0 mmol/L occurred in 5.3% and 7.4% of the two lorundrostat groups (2.1% and 3.2% after confirmation by repeat testing). The trial was “Not head-to-head with other classes of antihypertensive medications” and “Not a cardiovascular or kidney outcome trial”. As of November 2026 no posted results were located in the registry record, and participant disposition after randomization, discontinuations for adverse events, mean changes in potassium, sodium, and eGFR, and daytime, nighttime, and office blood pressure results by arm are not reported in the publication abstract, the presentation, the registry record, or the company releases.
Limitations stated in the trial presentation
Transform-HTN
Objective
Purpose stated in the ClinicalTrials.gov record
Purpose stated by the sponsor
Role of the trial in the new drug application
Scope of the AHA Scientific Sessions 2026 presentation
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2023-07-14” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-12-30” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-05” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Registered locations
Other study identifiers
Presentation of results
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Phase | “Phase 3” |
| Enrollment | “1076” |
Open-label treatment period, safety follow-up, and optional continuation
Double-blind randomized treatment withdrawal substudy
Timeline relative to the Launch-HTN double-blind period
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Additional criteria for the randomized treatment withdrawal substudy
Launch-HTN criteria that defined the presented cohort
Treatment
Registered arms and interventions
Open-label starting dose and background antihypertensive drugs
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Registered primary outcome measures
Efficacy endpoints in the AHA Scientific Sessions 2026 presentation
Prespecified endpoint: proportion achieving office systolic blood pressure below 130 mmHg
Safety endpoints and assessment periods
Placebo-controlled duration in the parent trial and the purpose of the extension
“First, the efficacy and safety of lorundrostat compared with placebo was evaluated for only 12 weeks. This is consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration. However, eligible participants had the option to continue in an open-label extension trial (NCT05968430), which intends to provide safety and efficacy information relevant to longer-term use of lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term exposure expected for drugs for chronic non-life-threatening conditions
Randomized withdrawal as a test of maintained effect in approved add-on products
Blood pressure reduction as the basis of cardiovascular benefit
Unattended automated office measurement in the parent trial
“After an initial 5-minute rest phase, 5 unattended seated measurements were performed with a 1-minute break between each reading; the last 4 measurements were used to calculate the mean and reduce within-participant variance in measuring BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment across all parent studies
Launch-HTN cohort enrolled and analyzed
Planned sample size
No evidence found.
Number randomized in the randomized treatment withdrawal substudy
No evidence found.
Description of analysis sets
Population for the registered primary outcome
Estimand and handling of missing data
Population for the duration of treatment and the eGFR equation
Results
Participant disposition
Enrollment, completion, and duration of treatment in the Launch-HTN cohort
Participants enrolled from Advance-HTN and Explore-CKD
No evidence found.
Baseline characteristics
Baseline characteristics of the Launch-HTN cohort (safety population)
| Characteristic | Lorundrostat (N=632) |
|---|---|
| Age, mean ±SD, years | “61.2 ± 10.5” |
| Female, n (%) | “292 (46.2)” |
| Black or African American, n (%) | “155 (24.5)” |
| Hispanic or Latino, n (%) | “248 (39.2)” |
| BMI ≥30 kg/m2, n (%) | “395 (62.5)” |
| eGFR, mean ±SD, mL/min/1.73 m2 | “92.7 ± 17.4” |
| Office SBP, mean ±SD, mmHg | “148.5 ± 11.9” |
| 2 antihypertensive drugs, n (%) | “262 (41.5)” |
| 3 or more antihypertensive drugs, n (%) | “370 (58.5)” |
| Thiazide or thiazide-like diuretic, n (%) | “601 (95.1)” |
| ACE inhibitor or ARB, n (%) | “546 (86.4)” |
| Calcium channel blocker, n (%) | “295 (46.7)” |
| Beta blockers, n (%) | “209 (33.1)” |
Baseline office systolic blood pressure of the efficacy population
Efficacy results
Primary endpoint: change in office systolic blood pressure from Launch-HTN baseline to week 48
Proportion with office systolic blood pressure below 130 mmHg at week 48
Randomized treatment withdrawal substudy: status
Randomized treatment withdrawal substudy: change in automated office systolic blood pressure from week 12 to week 16
No evidence found.
Efficacy in participants enrolled from Advance-HTN and Explore-CKD
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events during the 36-week open-label period
| Participants, n (%) | Lorundrostat (N=632) |
|---|---|
| Any treatment-emergent adverse event | “413 (65.3)” |
| Moderate intensity | “141 (22.3)” |
| Severe intensity | “20 (3.2)” |
| Treatment-emergent adverse event leading to study drug withdrawal | “37 (5.9)” |
| Hyperkalemia leading to study drug withdrawal | “10 (1.6)” |
| Any serious adverse event | “27 (4.3)” |
| Death | “0” |
| Treatment-related serious treatment-emergent adverse event (investigator determined) | “2 (0.3)” |
| Hyperkalemia requiring trial drug modification (adverse event of special interest) | “32 (5.1)” |
| Hyponatremia requiring trial drug modification (adverse event of special interest) | “28 (4.4)” |
| Hypotension with symptoms (adverse event of special interest) | “13 (2.1)” |
| Serum potassium >6.0 mmol/L, confirmed per protocol repeat testing | “16 (2.5)” |
Definition of adverse events of special interest requiring drug modification
Serious adverse events, discontinuations, and hyperkalemia stated by the sponsor
Kidney function and serum potassium over time
Overall tolerability conclusion of the presenters
Study limitations
Summary
Transform-HTN is a phase 3, single-group, open-label extension registered with 1,076 participants from three parent studies (Launch-HTN, Advance-HTN, and Explore-CKD). The only results available as of November 2026 are for the Launch-HTN cohort, presented as congress slides and a company press release on November 8, 2026; no peer-reviewed publication and no posted registry results were located, and the record lists a certification or extension request for results submission first submitted on July 15, 2026. Of 808 participants who received lorundrostat in Launch-HTN, 632 (78%) enrolled, so the cohort is limited to participants who completed the parent trial and chose to continue, which may favor participants who tolerated and responded to treatment. The primary endpoint is a within-group change from the Launch-HTN baseline, which includes the 12-week double-blind period; after the 12-week double-blind period there was no concurrent control group except during the 4-week withdrawal substudy, and in Launch-HTN the placebo group's automated office systolic blood pressure fell by 7.9 mm Hg at week 6, so the 17.8 mmHg change at week 48 cannot be attributed entirely to lorundrostat. The efficacy analysis (504 participants) excluded participants randomized to placebo in the withdrawal substudy, whereas the safety analysis included all 632; missing week 48 values were imputed with a shift factor based on the parent trial's placebo group. The randomized treatment withdrawal substudy, the only randomized comparison in the trial, is a registered primary outcome (change in automated office systolic blood pressure from extension week 12 to week 16) and is listed as completed, but neither its sample size nor its results were located in any public document. Only the office systolic blood pressure change and the proportion below 130 mmHg were prespecified; the biomarker results were not. Serum creatinine was measured by an enzymatic assay in Launch-HTN and a Jaffe assay in the extension, which limits comparison of eGFR across the two periods. No quality-of-life or patient-reported outcome was reported, and no results were located for participants who entered from Advance-HTN or Explore-CKD.
Interpretive limits of uncontrolled long-term studies
Target-HTN
Objective
Primary objective: safety, efficacy, and dose selection
“To compare the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, with placebo, and characterize dose-dependent safety and efficacy to inform dose selection in future trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Trial on the Safety and Efficacy of MLS-101 (Lorundrostat) in Patients With Uncontrolled Hypertension (Target-HTN) was designed to examine the safety and efficacy of lorundrostat at 5 different doses in participants with uncontrolled hypertension, with a specific aim of BP reduction among participants with obesity or suppressed renin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company description of the trial objective
Location and study date
Registered locations and study dates
| Field | Quoted record |
|---|---|
| Study start (actual) | “2021-07-01” |
| Primary completion (actual) | “2022-09-07” |
| Study completion (actual) | “2022-10-07” |
| Other study ID number | “MLS-101-201” |
| Sponsor | “Mineralys Therapeutics Inc.” |
Study design
Randomized, placebo-controlled, dose-ranging design
“Randomized, placebo-controlled, dose-ranging trial among adults with uncontrolled hypertension taking 2 or more antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this multicenter, prospective, randomized, placebo-controlled, dose-ranging, double-blind clinical trial among adults with uncontrolled hypertension” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered design details
| Field | Quoted record |
|---|---|
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |
Prescreening, placebo run-in, and 8-week treatment period
“Participants underwent 2 to 4 weeks of prescreening, a 2-week placebo run-in period to ensure eligibility, and then randomization and treatment for 8 weeks. A final visit was conducted 2 to 4 weeks following completion of the double-blind treatment (eFigure 1 in Supplement 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single-blind placebo run-in by renin stratum
Two cohorts defined by plasma renin activity
“An initial cohort of 163 participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and elevated plasma aldosterone (≥1.0 ng/dL) were enrolled, with subsequent enrollment of 37 participants with PRA greater than 1.0 ng/mL/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interim analyses and discontinuation of the two lowest doses
“An independent data and safety monitoring board performed an interim analysis in January 2022, and randomization to the 2 lowest doses of lorundrostat (12.5 mg once daily and 12.5 mg twice daily) was discontinued due to lack of consistent meaningful reduction of BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An additional interim analysis was performed following the last participant visit from cohort 1 and full enrollment of cohort 2 to guide dose selection in future studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly visits and blood pressure measurement schedule
“Following randomization, all participants’ study visits were conducted at weeks 1 through 8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-four-hour ambulatory BP monitoring was measured at baseline and once again prior to the 8-week visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial oversight and sponsor role
“The trial protocol was designed by Mineralys Therapeutics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An independent data monitoring committee oversaw patient safety. Cytel performed the statistical analysis, and the Cleveland Clinic Coordinating Center for Clinical Research (C5Research) independently confirmed the primary end-point analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Uncontrolled blood pressure on 2 or more antihypertensive medications
“Patients were eligible for trial enrollment if they were older than 18 years with a systolic automated office BP (AOBP) of 130 mm Hg or greater while taking 2 or more antihypertensive medications for at least 4 weeks at maximally tolerated doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renin and aldosterone criteria for each cohort
“Cohort 1 of the study enrolled participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and serum aldosterone level of 1.0 ng/dL or greater based on morning measurements, while cohort 2 enrolled participants with PRA of greater than 1.0 ng/mL/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key exclusion criteria
“Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA, estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2, morning serum cortisol level of less than 3 µg/dL, serum sodium level of less than 135 mmol/L, or hemoglobin A1c of 9% or greater.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A systolic AOBP of 175 mm Hg or greater, diastolic BP of 100 mm Hg or greater, or serum potassium level greater than 5.2 mmol/L was exclusionary in cohort 1, whereas exclusion criteria in cohort 2 were a systolic AOBP greater than 160 mm Hg, diastolic BP greater than 100 mm Hg, or serum potassium level greater than 4.8 mmol/L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered inclusion and exclusion criteria
“Background antihypertensive treatment of ≥ 2 drugs” (opens the source at this quote in a new tab)
“Serum cortisol ≥ 18 mcg/dL” (opens the source at this quote in a new tab)
“Subjects with body mass index > 40 kg/m2” (opens the source at this quote in a new tab)
“Strong CYP3A and CYP3A4 inducers” (opens the source at this quote in a new tab)
“Subjects who are night-shift workers” (opens the source at this quote in a new tab)
Treatment
Cohort 1: five lorundrostat regimens or placebo
Add-on to stable background antihypertensive therapy with morning dosing
Study outcomes
Rationale for using change in office systolic blood pressure as the primary endpoint
Primary endpoint: change in automated office systolic blood pressure at week 8
“The primary efficacy end point was change in systolic AOBP from baseline to the end of study week 8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Efficacy assessment with AOBP (average of the last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in a seated position) was measured weekly throughout the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered primary outcome measure
Blood pressure reduction as the basis of cardiovascular benefit
Systolic blood pressure reduction and major cardiovascular events
Unattended automated office blood pressure measurement
“AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because having an observer present when BP readings are obtained may lead to inaccurate values (eg, if the patient or observer is talking), it is preferred to have the patient in a room alone for BP measurements (ie, unattended AOBP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary efficacy endpoints
Registered secondary outcome measures
Safety, pharmacodynamic, and adverse events of special interest endpoints
“Additional safety and pharmacodynamic biomarker end points included changes in PRA, serum aldosterone, cortisol, potassium, and eGFR during the study. Prespecified adverse events of special interest were incidence of hyperkalemia with dose modification, hypotension with symptoms, and adrenal insufficiency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size rationale
“The study was designed to provide information regarding a safe and effective dose of lorundrostat for subsequent efficacy trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A sample size of 30 participants per group was estimated to provide the half-width of the 2-sided 90% CI of 3.8 mm Hg with a common standard deviation assumed to be 9 mm Hg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All analyses of cohort 2 of the study were exploratory in nature, and no formal sample size considerations were undertaken for this cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants screened and randomized
Registered enrollment
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “200” |
Participants randomized and analyzed for the primary endpoint by group
Description of analysis sets
Full analysis set and safety population
“Analyses were based on the full analysis set, defined as all randomized participants who received at least 1 dose of study medication. A safety analysis population was defined as all participants who took at least 1 dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mixed-model repeated-measures primary analysis
“The primary efficacy analysis was performed using a mixed-model repeated-measures approach with fixed effects of categorical terms for treatment, week, and treatment by week interaction, and baseline systolic AOBP as a fixed continuous covariate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of the primary end point was repeated in each prespecified subgroup, and these analyses were considered exploratory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Handling of intercurrent events
“The statistical analysis plan outlined intercurrent events (ICE) that would result in imputation of week 8 BP. Specifically, if rescue BP medications were initiated, the observed systolic BP at time of rescue medication initiation was imputed. Additionally, if participant withdrawal occurred before completion of the 8-week period for a treatment-related reason or worsening, the baseline systolic BP value was imputed as the week 8 measurement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary analyses and multiplicity
“All secondary efficacy end-point analyses are considered supportive, and any inferential statistics are considered descriptive in nature. No adjustment for multiplicity was performed due to the phase 2 exploratory intent of the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered analysis populations and cohort 2 comparison
Results
Participant disposition
Registered participant flow by group
| Disposition | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
|---|---|---|---|---|---|---|---|---|
| Started | “30” | “22” | “30” | “23” | “28” | “30” | “6” | “31” |
| Completed | “29” | “18” | “28” | “18” | “26” | “27” | “6” | “30” |
| Not completed | “1” | “4” | “2” | “5” | “2” | “3” | “0” | “1” |
| Adverse event | “0” | “0” | “0” | “1” | “0” | “0” | “0” | “0” |
| Lost to follow-up | “0” | “1” | “1” | “2” | “0” | “1” | “0” | “0” |
| Not specified by investigator | “0” | “3” | “0” | “0” | “1” | “0” | “0” | “0” |
| Protocol violation | “1” | “0” | “1” | “1” | “0” | “1” | “0” | “0” |
| Withdrawal by subject | “0” | “0” | “0” | “1” | “1” | “1” | “0” | “1” |
Lowest-dose groups closed after the interim analysis
Intercurrent events by group
“In the primary analysis population of cohort 1, participants receiving lorundrostat had ICE as follows: 100 mg once daily: 1 had ICE type 1 (initiation of rescue medication; systolic BP that triggered rescue medication is imputed), 4 had ICE type 3 (withdrawal from treatment for treatment-related reason or worsening; baseline systolic BP is imputed), and 3 had ICE type 4 (withdrawal from treatment for non–treatment-related reasons; mixed-model repeated-measures estimate); 50 mg once daily: 1 had ICE type 1; 25 mg twice daily: 1 had ICE type 3 and 2 had ICE type 4; 12.5 mg twice daily: 1 had ICE type 3; and 12.5 mg once daily: 1 had ICE type 1, 4 had ICE type 3, and 4 had ICE type 4. In the placebo group, 1 had ICE type 1 and 1 had ICE type 4. In the primary analysis population of cohort 2 receiving lorundrostat, 2 had ICE type 1, 2 had ICE type 3, and 1 had ICE type 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographics and baseline blood pressure of randomized participants
“Among randomized participants, the mean age was 65.7 (SD, 10.2) years, 60% were women, 36% were Black or African American, and 48% were of Hispanic or Latino ethnicity. At the time of randomization, 48% of participants had a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of greater than 30 and 40% had type 2 diabetes. Three or more antihypertensive medications were taken by 42% of the study population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohort 1 participants had a mean baseline systolic AOBP of 142.2 (SD, 12.5) mm Hg and a mean diastolic AOBP of 81.5 (SD, 9.7) mm Hg, whereas cohort 2 participants had a mean baseline systolic BP of 139.1 (SD, 8.7) mm Hg and diastolic BP of 79.1 (SD, 9.7) mm Hg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics by group
Registered age distribution and region of enrollment
| Characteristic | Total (200 participants) |
|---|---|
| Age younger than 65 years | “83” |
| Age 65 to 79 years | “104” |
| Age 80 years or older | “13” |
| Enrolled in the United States | “200” |
| Body mass index, mean (SD), kg/m^2 | “31.1(5.0)” |
| Seated automated office systolic blood pressure, mean (SD), mmHg | “141.6(12.0)” |
Efficacy results
Primary end point: automated office systolic blood pressure at week 8
Placebo-subtracted change in systolic blood pressure with once-daily doses
“At week 8, the placebo group demonstrated a change of −4.1 (SE, 2.6) mm Hg in systolic AOBP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the once-daily dose cohorts, the placebo-subtracted change in systolic AOBP was −1.5 mm Hg (90% CI, −8.3 to 5.3 mm Hg; P = .71) for 12.5 mg, −9.6 mm Hg (90% CI, −15.8 to −3.4 mm Hg; P = .01) for 50 mg, and −7.8 mm Hg (90% CI, −14.1 to −1.5 mm Hg; P = .04) for 100 mg. The change in BP demonstrated with the twice-daily doses, compared with placebo, showed similar BP reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because cohort 2 was an exploratory end point, no formal statistical testing was performed comparing lorundrostat with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Observed changes in office systolic blood pressure in participants with suppressed renin
“Following 8 weeks of treatment in participants with suppressed PRA, changes in office systolic blood pressure of −14.1, −13.2, −6.9, and −4.1 mm Hg were observed with 100 mg, 50 mg, and 12.5 mg once daily of lorundrostat and placebo, respectively. Observed reductions in systolic blood pressure in individuals receiving twice-daily doses of 25 mg and 12.5 mg of lorundrostat were −10.1 and −13.8 mm Hg, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Topline placebo-adjusted reductions reported by Mineralys
Secondary end point: automated office diastolic blood pressure at week 8
“The 50-mg once-daily dose of lorundrostat decreased diastolic AOBP by 5.5 mm Hg compared with placebo (90% CI, −9.4 to −1.5 mm Hg; P = .02). Other doses did not demonstrate statistically significant lowering of diastolic AOBP compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary end point: ambulatory 24-hour blood pressure
“Twenty-four-hour ambulatory BP monitoring results including mean overnight and central systolic BP as assessed by pulse-wave velocity are reported in eTables 3 and 4 in Supplement 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Measure | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
|---|---|---|---|---|---|---|---|---|
| Participants analyzed | “26” | “16” | “26” | “15” | “28” | “24” | “0” | “27” |
| Change in 24-hour mean SBP, least squares mean (SE), mmHg | “-1.01(2.38)” | “-5.78(3.03)” | “-9.05(2.38)” | “-2.51(3.15)” | “-4.86(2.34)” | “-6.34(2.5)” | Not reported | “-1.02(2.64)” |
| Change in 24-hour mean DBP, least squares mean (SE), mmHg | “-0.90(1.46)” | “-5.14(1.85)” | “-6.03(1.45)” | “-2.34(1.91)” | “-3.64(1.40)” | “-6.14(1.51)” | Not reported | “-0.07(1.69)” |
Secondary end point: blood pressure below 130/80 mm Hg at week 8
Exploratory subgroups: obesity and thiazide-type diuretic use
“Most notably, participants with obesity demonstrated greater BP lowering in response to lorundrostat. Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo. With 100 mg once daily of lorundrostat, participants with obesity saw a −12.3 mm Hg (90% CI, −21.6 to −3.1 mm Hg) change in systolic AOBP compared with placebo. Among individuals with a BMI of 25 to 30, the BP changes were 2.2 mm Hg (90% CI, −7.4 to 11.8 mm Hg) and −4.5 (90% CI, −14.5 to 5.5 mm Hg) for the 50-mg and 100-mg once-daily doses, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, participants taking a thiazide-type diuretic randomized to 50 mg or 100 mg once daily of lorundrostat demonstrated changes of −12.9 mm Hg (90% CI, −21.2 to −4.7 mm Hg) and −10.0 mm Hg (90% CI, −21.2 to −1.6 mm Hg) in systolic AOBP compared with placebo. Blood pressure decreases were attenuated among participants not taking a diuretic (eTable 1 in Supplement 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory cohort 2: participants without suppressed renin
“Participants with PRA of greater than 1.0 ng/mL/h (cohort 2) randomized to 100 mg once daily of lorundrostat demonstrated a similar change in mean systolic AOBP of −11.4 (SD, 2.5) mm Hg compared with those randomized to 100 mg once daily with suppressed plasma renin in cohort 1. The least-squares mean systolic AOBP difference between the 100-mg once-daily cohorts was 0.74 mm Hg (90% CI, −5.4 to 6.9 mm Hg).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamic biomarkers: aldosterone, renin activity, and cortisol
“Lorundrostat resulted in reductions in serum aldosterone at all doses, whereas the cohort 1 placebo group saw an increase in mean serum aldosterone level of 0.14 (SD, 3.68) ng/dL. The 12.5-mg, 50-mg, and 100-mg once-daily doses in cohort 1 reduced mean serum aldosterone by 1.05 (SD, 4.33) ng/dL, 2.56 (SD, 3.72) ng/dL, and 2.88 (SD, 4.44) ng/dL, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In cohort 2, 100 mg daily of lorundrostat decreased mean serum aldosterone by 1.19 (SD, 5.38) ng/dL. Anticipated increases in PRA were observed ranging between 0.78 (SD, 3.44) ng/mL/h to 4.65 (SD, 11.27) ng/mL/h in cohort 1, and there were small increases in serum cortisol (eTable 2 in Supplement 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Once-daily compared with twice-daily dosing
“The 50-mg once-daily dose of lorundrostat lowered office BP to a similar degree as the 100-mg once daily dose, but resulted in fewer adverse events, including fewer episodes of hyperkalemia. Lorundrostat has a relatively short half-life, and once-daily dosing resulted in a 25% lower mean change in serum potassium when 50 mg once daily was compared with 25 mg twice daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Deaths, serious adverse events, and overall adverse events
“No participant deaths occurred during the trial. Three serious adverse events occurred; only 1 was deemed treatment related. A participant randomized to 100 mg once daily of lorundrostat in cohort 2 had worsening of hyponatremia necessitating stopping the drug. A total of 110 participants (55%) experienced any adverse event during the trial (Table 3). Most adverse events were classified as mild by investigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant was identified with worsening of preexisting coronary artery disease and 1 participant was found to have metastatic cancer in their peritoneum.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events and serum potassium changes by group
Hyperkalemia and hypotension
“Prespecified adverse events of special interest included 3 participants (2%) with hypotension. Mean serum potassium increases were similar across all lorundrostat doses, including increases of 0.25 mmol/L in the 50-mg and 100-mg once-daily groups. Six participants (3.6%) had serum potassium levels above 6.0 mmol/L during the trial (Table 3). No instances of hyperkalemia required intervention beyond discontinuation or reduction in the dose of lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Affected individuals were counted once at highest-grade abnormality. Hemolyzed blood samples with serum potassium levels that were not reproducible on repeat testing were not included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cortisol and adrenal function
“No adrenocortical insufficiency occurred during the trial. Cosyntropin stimulation testing in participants randomized to 100 mg once daily in both cohort 1 and cohort 2 was normal, with stimulated values of cortisol greater than 18 µg/dL in all individuals receiving cosyntropin (eFigure 4 in Supplement 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estimated glomerular filtration rate
“Declines in eGFR paralleled the reduction in systolic AOBP and were consistent with expected lowering of intraglomerular pressures (eTable 2 in Supplement 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Examples of more prevalent adverse events included hyperkalemia and decline in estimated glomerular filtration rate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered serious and other adverse events by group
Company summary of potassium findings
Study limitations
Summary
Target-HTN was a phase 2, dose-ranging trial that randomized 200 participants at sites in the United States to five lorundrostat regimens or placebo for 8 weeks, with no adjustment for multiplicity and with treatment differences reported as 90% confidence intervals. In cohort 1, the primary analysis included 19 to 29 participants per group, and the authors state that “each studied dose had a limited sample size”. Randomization to the 12.5 mg once-daily and 12.5 mg twice-daily groups stopped after the January 2022 interim analysis, and two interim analyses were performed in total. Cohort 1 enrolled only participants with suppressed renin; cohort 2 (37 participants, 6 receiving placebo) was exploratory, with no formal statistical testing against placebo. Sustained hypertension was not confirmed by 24-hour ambulatory monitoring before randomization, which the authors associate with “a prominent white-coat effect” in the 50 mg once-daily group. Participants with an eGFR below 60 mL/min/1.73 m2, or with serum potassium above 5.2 mmol/L (cohort 1) or 4.8 mmol/L (cohort 2), were excluded. The registered results define the proportion at goal as blood pressure of 130/80 mmHg or lower at week 8, while the publication describes it as below 130/80 mm Hg at week 7 or 8. The trial protocol was designed by the sponsor, Mineralys Therapeutics, which also provided input on the manuscript.
Limitations stated by the authors
“This trial has limitations. First, multiple dosing regimens were tested for efficacy, and each studied dose had a limited sample size. Second, 24-hour ambulatory BP monitoring was not used to confirm sustained hypertension before randomization, and this resulted in a disproportionate percentage of participants with a prominent white-coat effect in the 50-mg once-daily lorundrostat group. Third, cohort 1 of this trial selected participants with suppressed renin at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fourth, 2 interim analyses were performed; multiple interim analyses would not be appropriate in subsequent confirmatory trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Need for confirmatory studies
Sponsor role in the protocol and manuscript
“The trial protocol was designed by Mineralys Therapeutics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The first author (L.J.L.) wrote the first version of the manuscript and made revisions following input from coauthors and the sponsor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Explore-CKD
Objective
Purpose stated in the ClinicalTrials.gov record
Aim stated in the published report
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual)” (opens the source at this quote in a new tab)
“2023-12-14” (opens the source at this quote in a new tab)
“Primary Completion (Actual)” (opens the source at this quote in a new tab)
“2025-02-27” (opens the source at this quote in a new tab)
“Study Completion (Actual)” (opens the source at this quote in a new tab)
“2025-04-23” (opens the source at this quote in a new tab)
“Results First Posted” (opens the source at this quote in a new tab)
Registered locations
Sites and enrollment period in the published report
Other study identifiers
Study design
Two-period, two-sequence crossover design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “60” |
Blood pressure measurement procedure
Eligibility criteria
Key inclusion and exclusion criteria in the published report
Major inclusion criteria in the ClinicalTrials.gov record
Major exclusion criteria in the ClinicalTrials.gov record
Ages eligible in the ClinicalTrials.gov record
Chronic kidney disease stages described by the sponsor
Treatment
Lorundrostat 25 mg or placebo once daily on background ACEi or ARB and SGLT2 inhibitor
Treatment sequences in the ClinicalTrials.gov record
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Blood pressure control in chronic kidney disease
Clinical relevance of the systolic blood pressure reduction stated by the investigators
Blood pressure reduction as the basis of cardiovascular benefit in FDA labeling guidance
Systolic blood pressure reduction and major cardiovascular events in an individual participant data meta-analysis
Automated office blood pressure measurement
“AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unattended compared with attended automated office blood pressure
Rationale for albuminuria as an exploratory endpoint
Rationale for cystatin C estimated glomerular filtration rate
Safety endpoints and adverse events of special interest
Statistical analysis description
Number of participants (Planned and analyzed)
Participants screened and randomized in the published report
Enrollment in the ClinicalTrials.gov record
Participants analyzed in the posted results
| Analysis | Placebo | Lorundrostat |
|---|---|---|
| Primary outcome, overall number of participants analyzed | “58” | “58” |
| All-cause mortality, affected / at risk (%) | “0/57 (0.00%)” | “0/58 (0.00%)” |
Description of analysis sets
Estimand and handling of missing data for the primary endpoint
Crossover model, sensitivity analysis, and parallel-group analyses
Adverse event reporting in the posted results
Results
Participant disposition
Screening, randomization, and open-label extension enrollment
Baseline characteristics
Demographic and disease characteristics in the published report
Baseline characteristics table (N = 59)
| Characteristic | Value |
|---|---|
| Age, years, mean ± SD | “64.6 ± 10.14” |
| Age 75 years or older, n (%) | “13 (22.0)” |
| Male, n (%) | “41 (69.5)” |
| Female, n (%) | “18 (30.5)” |
| White, n (%) | “39 (66.1)” |
| Black or African American, n (%) | “10 (16.9)” |
| Hispanic or Latino, n (%) | “25 (42.4)” |
| Body mass index, kg/m2, mean ± SD | “33.1 ± 7.10” |
| Seated automated office systolic blood pressure, mm Hg, mean ± SD | “148.9 ± 10.37” |
| Seated automated office diastolic blood pressure, mm Hg, mean ± SD | “82.0 ± 10.49” |
| eGFR (cystatin C), ml/min per 1.73 m2, mean ± SD | “43.0 ± 14.97” |
| eGFR (creatinine), ml/min per 1.73 m2, mean ± SD | “54.6 ± 21.08” |
| UACR (24 hr), mg/g, geometric mean ± SD | “559 ± 2.55” |
| Two or fewer antihypertensive medications, n (%) | “21 (35.6)” |
| Three or more antihypertensive medications, n (%) | “38 (64.4)” |
| β-Blockers, n (%) | “28 (47.5)” |
| Selective calcium-channel blockers with mainly vascular effects, n (%) | “30 (50.8)” |
| Type 2 diabetes mellitus, n (%) | “45 (76.3)” |
| SGLT2i-naive at screening, n (%) | “26 (44.1)” |
Baseline systolic blood pressure by sequence in the posted results
| Group | Seated automated office systolic blood pressure, mmHg, mean (SD) |
|---|---|
| Cohort 1 (lorundrostat, then placebo) | “147.008(9.8704)” |
| Cohort 2 (placebo, then lorundrostat) | “150.802(10.6962)” |
| Total | “148.873(10.3731)” |
Efficacy results
Primary endpoint: change in automated office systolic blood pressure at week 4
Period and carryover effects
Primary outcome in the posted results
| Measure | Placebo | Lorundrostat |
|---|---|---|
| Least squares mean change from baseline, mmHg | “-1.755” | “-9.253” |
| 90% confidence interval | “(-4.966 to 1.455)” | “(-12.453 to -6.053)” |
Albuminuria and proteinuria
Estimated glomerular filtration rate
Topline results table in the sponsor release
| Measure | Placebo | Lorundrostat 25 mg | Placebo-adjusted |
|---|---|---|---|
| Change in systolic BP (mmHg), primary endpoint | “-1.76” | “-9.25” | “-7.5 (p=0.0024)” |
| Change in spot UACR (mg/g) | “-6.60%” | “-30.51%” | “-25.60% (p=0.0015)” |
| Change in eGFR, cystatin C (mL/min/1.73m2) | “-2.20%” | “-6.78%” | “-4.58% (p=0.0362)” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events
Overview of treatment-emergent adverse events, n (%) and number of events
| Event | Placebo (n = 57) | Lorundrostat (n = 58) |
|---|---|---|
| TEAEs | “19 (33.3) [36]” | “29 (50.0) [54]” |
| Treatment-related TEAEs | “8 (14.0) [9]” | “16 (27.6) [24]” |
| Serious adverse events | “0 (0.0) [0]” | “2 (3.4) [4]” |
| Adverse events of special interest | “1 (1.8) [1]” | “10 (17.2) [13]” |
| TEAEs leading to discontinuation of the trial drug | “1 (1.8) [1]” | “2 (3.4) [3]” |
| TEAEs leading to dose modification of the trial drug | “4 (7.0) [4]” | “12 (20.7) [15]” |
| Death | “0 (0.0) [0]” | “0 (0.0) [0]” |
Adverse events of special interest and discontinuations
Hyperkalemia
Sodium, kidney function, and cortisol
Serious adverse events in the posted results
| Event | Placebo, affected / at risk (%) | Lorundrostat, affected / at risk (%) |
|---|---|---|
| Total | “0/57 (0.00%)” | “2/58 (3.45%)” |
| Influenza | “0/57 (0.00%)” | “1/58 (1.72%)” |
| Hyperkalaemia | “0/57 (0.00%)” | “1/58 (1.72%)” |
| Acute kidney injury | “0/57 (0.00%)” | “1/58 (1.72%)” |
Other adverse events in the posted results (frequency threshold 2%)
| Event | Placebo, affected / at risk (%) | Lorundrostat, affected / at risk (%) |
|---|---|---|
| Total | “18/57 (31.58%)” | “29/58 (50.00%)” |
| Glomerular filtration rate decreased | “2/57 (3.51%)” | “6/58 (10.34%)” |
| Hyperkalaemia | “2/57 (3.51%)” | “9/58 (15.52%)” |
| Hyponatraemia | “3/57 (5.26%)” | “3/58 (5.17%)” |
| Hypotension | “2/57 (3.51%)” | “3/58 (5.17%)” |
| Orthostatic hypotension | “1/57 (1.75%)” | “2/58 (3.45%)” |
| Diastolic hypotension | “1/57 (1.75%)” | “2/58 (3.45%)” |
Study limitations
Summary
Explore-CKD was a phase 2, two-period, two-sequence crossover trial with 4-week treatment periods separated by a 4-week washout. The publication reports 59 randomized participants at 42 sites in the United States; the registry lists an enrollment of 60 and 44 locations. One dose, lorundrostat 25 mg once daily, was studied. The primary endpoint was the placebo-adjusted change in automated office systolic blood pressure; albuminuria, proteinuria, and eGFR were exploratory endpoints, and no kidney or cardiovascular outcome was assessed. The investigators state that the 4-week treatment period “does not assess the durability of blood pressure lowering or longer-term safety and clinical outcomes” and that the findings “will require confirmation in a larger, longer-duration, parallel-arm trial”. Participants with serum potassium above 5.0 mmol/L at screening were excluded, which, with the short treatment duration, the investigators state “could underestimate hyperkalemia risk in routine clinical practice”; hyperkalemia was reported in 9 of 58 participants (15.5%) during lorundrostat treatment and 2 of 57 (3.5%) during placebo. The registry requires stable ACEi or ARB treatment for at least 2 months before screening, and the publication states at least 4 weeks. The trial was designed and funded by Mineralys Therapeutics, three authors are company employees, and no health-related quality of life or patient-reported outcome was reported.
Limitations stated by the investigators
Sponsor role and author disclosures
Explore-OSA
Objective
Purpose stated in the ClinicalTrials.gov record
Objective stated in the congress abstract
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual)” (opens the source at this quote in a new tab)
“2025-02-28” (opens the source at this quote in a new tab)
“Primary Completion (Actual)” (opens the source at this quote in a new tab)
“2025-12-17” (opens the source at this quote in a new tab)
“Study Completion (Actual)” (opens the source at this quote in a new tab)
Registered locations
Planned number of sites at trial initiation
Other study identifiers
Results reporting status in the ClinicalTrials.gov record
Study design
Randomized, double-blind, placebo-controlled crossover design in the congress abstract
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “48” |
Exploratory two-period, two-sequence design described by the sponsor
Eligibility criteria
Key eligibility criteria in the congress abstract
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Ages eligible in the ClinicalTrials.gov record
Treatment
Lorundrostat 50 mg or placebo once daily in the evening
Treatment sequences in the congress abstract
Interventions and positive airway pressure use in the ClinicalTrials.gov record
Study outcomes
Rationale for using Apnea-Hypopnea index as the primary endpoint
Sponsor rationale for an effect on upper airway obstruction
Investigator rationale for aldosterone synthase inhibition in obstructive sleep apnea
Apnea-hypopnea index as the most studied measure of sleep apnea severity
“OSA has well established cardiovascular and neurocognitive sequelae, although the optimal metric to assess its severity and/or potential response to therapy remains unclear.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The apnea-hypopnea index (AHI) is well established; thus, we review its history and predictive value in various different clinical contexts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the AHI is often criticized for its limitations, it remains the best studied metric of OSA severity, albeit imperfect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Apnea-hypopnea index as the primary endpoint of the trials supporting an approved obstructive sleep apnea indication
Apnea-hypopnea index as a phase 3 primary endpoint
“The primary end point was the change in the apnea–hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The AHI was measured by laboratory polysomnography at screening, week 20, and week 52.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key secondary endpoint: office systolic blood pressure
Key secondary objective stated at trial initiation
Registered secondary outcome measures
Rationale for blood pressure endpoints in obstructive sleep apnea
Systolic blood pressure reduction and major cardiovascular events
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment at trial initiation
Enrollment in the ClinicalTrials.gov record
Participants reported in the topline release
Participants reported in the congress abstract
Description of analysis sets
Parallel-arm and crossover analyses
Results
Participant disposition
No evidence found.
Baseline characteristics
Body mass index, apnea-hypopnea index, and systolic blood pressure at baseline
Efficacy results
Summary: systolic blood pressure figures in the congress abstract and the company releases
The congress abstract reports the preplanned parallel-arm analysis of the first treatment period as a placebo-adjusted reduction in systolic blood pressure of 10.1 mmHg (P=0.0089). The NDA acceptance release and the AHA Hypertension 2026 release report within-group reductions of 11.1 mmHg with lorundrostat (p<0.0001) and 1.0 mmHg with placebo (p=NS) at week 4, and the NDA acceptance release attributes these figures to the pre-planned parallel arm analysis of the first period; the difference between the two within-group figures is 10.1 mmHg. The abstract and the NDA acceptance release both report a placebo-adjusted reduction of 6.2 mmHg (P<0.0003) in the crossover analysis of both treatment periods. The NDA acceptance release reports topline results.
Primary endpoint: apnea-hypopnea index not met
Office systolic blood pressure: placebo-adjusted estimates in the congress abstract
Office systolic blood pressure: within-group changes and crossover estimate in the topline release
Nighttime blood pressure
No evidence found.
Health-related quality of life and patient-reported outcomes
Functional Outcomes of Sleep Questionnaire-10
Epworth Sleepiness Scale and PROMIS sleep measures
No evidence found.
Safety results
Serious adverse events and tolerability in the congress abstract
Study limitations
Summary
Explore-OSA was a phase 2 crossover trial with two 4-week treatment periods separated by a 2-week washout; the registry lists 48 enrolled participants and the congress abstract describes 47. The primary endpoint, the placebo-adjusted change in apnea-hypopnea index at week 4, showed “no difference in AHI response between lorundrostat- and placebo-treated participants”. Office systolic blood pressure was a secondary endpoint, and the public results come from a congress abstract and company releases; no peer-reviewed publication or posted registry results were located, and the registry record shows a certification/extension submission dated 2026-08-17. The registry lists nighttime average systolic blood pressure as the first secondary outcome measure and also lists the Epworth Sleepiness Scale and two PROMIS sleep measures; no result for any of these was located in the public documents. The parallel-arm systolic blood pressure estimate uses the first treatment period alone, and the abstract and the company releases state it differently. The abstract states that “more than a third of participants were using PAP therapy”. Public safety reporting is limited to the absence of serious adverse events and of serum potassium values above 5.5 mmol/L. Eligibility excluded participants with eGFR below 45 mL/min/1.73 m2 and participants taking a GLP-1 agonist, and the registry lists 27 locations.
Conclusions stated by the investigators
Topline status of the March 2026 results
MT-4129-E01
Objective
Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses
“This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of lorundrostat in healthy adult participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This first‐in‐human dose escalation study evaluates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple oral doses of lorundrostat, a highly selective CYP11B2 inhibitor. In addition, this study also compared lorundrostat PK in females and males and older adult (≥65 years old) and younger adult participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered purpose and official title
Concentration-QTc evaluation within the first-in-human study
Location and study date
Single center in the Netherlands, November 2016 to May 2017
Registered site, sponsor, and dates
| Field | Quoted record |
|---|---|
| Location | “Pharmaceutical Research Associates (PRA) Health Sciences” |
| Sponsor | “Tanabe Pharma Corporation” |
| Other study ID number | “MT-4129-E01” |
| Study start | “2016-11” |
| Primary completion (actual) | “2017-05” |
| Study completion (actual) | “2017-05” |
Ethics approval and contract research organization
“The study was approved by the local independent ethics committee; the BEBO foundation in Assen, Netherlands; and the Central Committee on Research Involving Human Subjects in The Hague, Netherlands; and conducted according to the provisions of the Declaration of Helsinki.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thijs van Iersel and Jan Jaap van Lier are employees of ICON, the CRO which conducted the clinical study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Four-part, randomized, double-blind, placebo-controlled design
“A four‐part, randomized, double‐blind, placebo‐controlled, first‐in‐human study was performed (single‐center in the Netherlands; November 16, 2016–May 01, 2017) to determine the safety, tolerability, PK, and PD of single ascending doses (SADs; part 1) and multiple ascending doses (MADs; part 2) of lorundrostat free base in a capsule in healthy participants (EudraCT Number: 2016–003500‐32).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study also assessed sex‐ (part 3) and age‐related (part 4) effects on the PK of a single dose of lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory food comparison
“An exploratory comparison of the effect of food on PK profiles of lorundrostat was also performed by assessing single‐dose PK profiles of lorundrostat in the fasted state (part 1) vs. PK profiles of lorundrostat in the fed state (part 2 after the first‐dose administered).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sentinel dosing and dose escalation rules
“All cohorts included two sentinel participants of whom one received lorundrostat and one received matching placebo. The remaining six participants, of whom five received lorundrostat and one received placebo, were dosed ≥24 h later.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Doses were administered in an ascending order per cohort. After each cohort, all safety data were reviewed prior to initiating the next dose cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Progression to the next dose level was based on available data from part 1 and the preceding dose cohort in part 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered design details
| Field | Quoted record |
|---|---|
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |
| Primary purpose | “Other” |
Holter electrocardiograms matched to pharmacokinetic sampling
Eligibility criteria
Healthy Caucasian men, women, and older men
“Healthy male Caucasian participants (parts 1 and 2) aged 18–55 years (inclusive), healthy non‐pregnant and non‐lactating female Caucasian participants (part 3) aged 18–55 years (inclusive), and healthy male Caucasian participants aged ≥65 years (part 4) were eligible.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered inclusion and exclusion criteria
Treatment
Part 1: single ascending doses of 5 to 800 mg, fasted
“In part 1, in each dose cohort, six participants were randomized to receive a single dose of lorundrostat and two participants were randomized to receive matching placebo in the fasted state.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The dosing cohorts were 5, 10, 20, 50, 100, 200, 400, and 800 mg (5‐mg starting dose rationale provided in Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part 2: once-daily doses of 40, 120, or 360 mg for 7 days, fed
“In part 2, in each cohort, nine participants received daily doses of lorundrostat and three participants received matching placebo in the fed state from Day 1 to Day 7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The final dose levels of lorundrostat for part 2 were 40, 120, and 360 mg. An adrenocorticotropic hormone (ACTH) challenge test was performed on Day ‐2 and Day 6 to evaluate the lorundrostat selectivity for aldosterone synthesis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Parts 3 and 4: single 100 mg dose in women and in men aged 65 years or older
“In one cohort of eight females (part 3) and one cohort of eight males aged ≥65 years (part 4), six participants were randomized to receive a single 100‐mg dose of lorundrostat and two participants were randomized to receive matching placebo in the fasted state in each part. The results were compared with those at the same dose in part 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capsule formulation relative to the phase 2 tablet
“The lorundrostat capsule formulation used in the first‐in‐human studies reported here is equivalent to ~50% of exposure seen in the tablet formulation used in the phase II study (doses used in the phase II study included 12.5 mg once daily and twice daily, 25 mg twice daily, 50 mg once daily, and 100 mg once daily).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using adverse events as the primary endpoint
Registered primary outcome measures
Safety assessments in the publication
“Safety assessments included treatment‐emergent adverse events (TEAEs), treatment‐related TEAEs, vital signs, 12‐lead electrocardiograms (ECGs), clinical laboratory evaluations, and physical examinations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Purpose of phase 1 studies in federal regulation
Rationale for cortisol and ACTH-stimulation safety assessments
“CYP11B1, a key enzyme in glucocorticoid biosynthesis, has a high homology to CYP11B2 (>93%). High selectivity for CYP11B2 over CYP11B1 is an essential characteristic for a successful aldosterone synthase inhibitor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Osilodrostat, the first aldosterone synthase inhibitor, lacked high selectivity, resulted in blunted adrenocorticotropic hormone‐stimulated cortisol release in some patients, and instead became a treatment for Cushing's disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for the concentration-QTc analysis
Registered secondary pharmacokinetic and pharmacodynamic outcome measures
Statistical analysis description
Number of participants (Planned and analyzed)
Participants screened and randomized
“A total of 245 participants were screened, of which 116 were randomized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Field | Quoted record |
|---|---|
| Enrollment (estimated) | “116” |
Participants per part
“Part 1 (SAD) included 64 male participants between 18 and 55 years old. Part 2 (MAD) included 36 male participants between 19 and 54 years of age. Part 3 (sex effect) included eight female participants between 20 and 35 years of age. Part 4 (age effect) included eight male participants between 68 and 80 years of age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants in the concentration-QTc analysis groups
Description of analysis sets
Safety, pharmacokinetic, and pharmacodynamic analysis sets
“Safety analyses used the safety analysis set (all participants who received at least one dose of study drug).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All PK analyses used the PK analysis set (all participants who received at least one dose of study drug other than placebo and had PK data considered sufficient and interpretable).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All PD analyses used the PD analysis set (all participants who received at least one dose of study drug, had at least one post‐dose PD assessment, and PD data considered sufficient and interpretable).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose proportionality, sex, age, and food comparisons
“Dose proportionality was concluded if the 95% confidence interval (CI) for slope (β) included the value 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Difference in least square means and corresponding 90% CI were back‐transformed to obtain the estimates of geometric mean ratios and their CI for females vs. males and participants ≥ 65 years old vs. 18–55 years old. The result was judged to be statistically significant if the 90% CI did not include 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No formal statistical comparison was performed for an exploratory comparison of PK between fasted (part 1) and fed (part 2, after the first‐dose administered) states.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic and QTc analysis set
Results
Participant disposition
Withdrawal for sinus tachycardia in the 360 mg cohort
“One participant in cohort 3 of part 2 was withdrawn on Day 2 because of an AE of sinus tachycardia (117 bpm) before dosing on Day 2, and he received only one dose of 360 mg lorundrostat on Day 1 (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographics by dose group and part
Efficacy results
In vitro selectivity for CYP11B2 over CYP11B1
“Lorundrostat inhibited hCYP11B2 and hCYP11B1 with inhibition constant values of 1.27 nmol/L and 475 nmol/L, respectively. These results indicate that lorundrostat inhibits CYP11B2 with 374‐fold selectivity over CYP11B1 (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single-dose pharmacokinetics
“Following single oral doses across 5–800 mg, plasma drug concentration–time profiles demonstrated rapid absorption with a median time to maximum concentration (T max) 1.0–1.5 h (Table 3; Figure 1b); the mean terminal half‐life (t 1/2) ranged from 7.9 to 10.5 h, and apparent clearance was comparable, ranging from 18.7 to 27.6 L/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the estimate of the slope (95% CI) for C max versus dose was 1.104 (1.043–1.164), and a slightly greater than dose proportional increase in C max was observed over the range 5–800 mg (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiple-dose pharmacokinetics and accumulation
“A steady state was achieved by approximately Day 5 and very slight accumulation of lorundrostat was observed following multiple dosing compared with Day 1, with the mean rate of accumulation values for AUC0–24 ranging from 1.15 to 1.19 across the entire dose range. Consistent with single‐dose administration, the mean t 1/2 values on Day 7 ranged from 9.1 to 11.9 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma pharmacokinetic parameters by dose
Urinary excretion of unchanged drug and renal clearance
“After a single dose of 40–360 mg of lorundrostat on Day 1, the fraction of the dose excreted in the urine as unchanged was low, with mean values ranging between 1.2%–1.8%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 7 days of once‐daily doses of lorundrostat, the fraction of the dose excreted in the urine as unchanged drug was low for all multiple‐dose levels, with mean values ranging between 2.3% and 2.6%. The fraction of the lorundrostat dose excreted remained consistent over the multiple‐dose range tested. Renal clearance was low and generally similar across all multiple‐dose levels (mean CLR ranging between 0.4 and 0.6 L/h on Day 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effects of sex, age, and food on pharmacokinetics
“In part 3 of the study, after a single 100‐mg dose of lorundrostat, there was no statistically significant difference between lorundrostat exposure in females and males (Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In part 4, there was no statistically significant difference between older adult and younger adult lorundrostat exposures (Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the dose escalation data of the first cohort in part 2 where lorundrostat was administered in the fed state, the PK profile did not appear to be affected compared with part 1 where lorundrostat was administered in the fasted state.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Separate from the study we report in this article, a formal food effect study has been conducted and confirms lack of effect of food on the absorption and PK of lorundrostat (tablet formulation; data on file).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma aldosterone suppression after single doses
“At the lower dose levels (lorundrostat 5–50 mg), the PAC returned to values near baseline within 24 h post‐dose. At the higher dose levels (lorundrostat 100–800 mg), the reduction of PAC was sustained until 24 h post‐dose. PAC showed maximum decreases at 4 h and 8 h post‐dose of ~80% compared with placebo. Single doses of lorundrostat, ranging from 10 to 800 mg reduced the AUC0–24 for PAC in a dose‐dependent manner, with statistically significant decreases ranging from 36% to 77% vs. placebo (Figure 2b; Table S5) without effecting cortisol (Figure 2c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone after multiple doses and rebound after the last dose
“Consistent with the SAD cohorts, multiple‐dose lorundrostat data demonstrated that for all dose levels tested, PAC decreased in an apparent dose‐dependent manner between 2 and 12 h post‐dose on Day 7 (Figure 2d). From 24 h after the last dose on Day 7, a clear rebound in PAC ranging from 73% to 163% compared with placebo was observed at all multiple‐dose levels of lorundrostat. These increases were sustained at least until Day 10, 3 days after the last dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ACTH-stimulated aldosterone and cortisol
“During non‐ACTH challenge conditions, no relevant changes from baseline were observed for serum cortisol concentrations and plasma 11‐deoxycortisol concentrations during multiple dosing of lorundrostat. At all multiple‐dose levels, lorundrostat completely blunted the ACTH‐stimulated aldosterone response on Day 6 compared with placebo, while there was no effect on the cortisol response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renin activity, 11-deoxycorticosterone, and urinary sodium
“Once‐daily administration of lorundrostat at doses ranging from 40 to 360 mg increased plasma renin activity and serum 11‐DOC compared with placebo (Figure 3a,b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Urine sodium and urinary log10 (10 × Na+/K+) ratio were increased at all dose levels tested in the SAD, consistent with reduced aldosterone signaling (Figure 3d). In the MAD, the urine sodium and urinary log10 (10 × Na+/K+) ratio was initially increased on Day 1 at all dose levels, but the ratio returned to baseline levels at the next sampling timepoint at the end of the dosing period on Day 7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Implications for dose selection
“Given that the PD effects on renal electrolyte regulation were near maximum at 120 mg daily and the excessive 11‐DOC accumulation observed at dose of 360 mg once daily, the data suggest that the dose selection for the treatment of hypertension should avoid the higher dose level and focus on doses up to 120 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Serious and overall treatment-emergent adverse events
“Lorundrostat was well tolerated and no serious TEAEs occurred during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]). Across all cohorts, dizziness (of mild intensity) was reported by nine (10.3%) lorundrostat‐treated participants compared with one (3.4%) placebo‐treated participant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no clinically significant findings with respect to clinical laboratory, vital signs, ECGs, or physical examination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related adverse events after single doses
Treatment-related adverse events after multiple doses
“There were no treatment‐related TEAEs in the Sex Effect Part 3 cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These observations suggest that a stimulus–response reaction to some of the study procedures was more plausible than a relationship to the study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum potassium during multiple dosing
“Within 2 days of initiation of lorundrostat treatment, serum potassium rose in all three dose cohorts (part 2) by group mean values ranging from 0.28 to 0.38 mmol/L and remained elevated throughout the remainder of the 7 days of treatment. There was a maximum mean increase of 0.44 mmol/L after 40 mg on Day 8, 0.6 mmol/L after 120 mg on Day 7, and 0.48 mmol/L after 360 mg on Day 6. None of the subjects reached the stopping criterion for potassium of 6.0 mmol/L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upon cessation of lorundrostat treatment, serum potassium levels rapidly fell toward pretreatment baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concentration-QTc results
Exposure margin and waiver of a thorough QT study
Heart rate, PR, and QRS intervals
Study limitations
Summary
MT-4129-E01 randomized 116 healthy white participants at one center in the Netherlands. Parts 1 and 2 enrolled men aged 18 to 55 years only, and the effects of sex and of age were each assessed in one cohort of 8 participants, 6 of whom received a single 100 mg dose. Multiple dosing lasted 7 days, so the study gives no information on longer treatment or on people with hypertension. Lorundrostat was given as a capsule whose exposure the authors state is about 50% of that of the tablet used in the phase 2 study, the comparison of fed and fasted pharmacokinetics was exploratory with no formal statistical comparison, and the formal tablet food effect study is described as “data on file”. The ClinicalTrials.gov record lists enrollment as estimated. The concentration-QTc analysis is reported in a congress poster by authors from Mineralys Therapeutics and Clario. The publication states that the studies it reports were funded by Mineralys Therapeutics, while the registry record names Tanabe Pharma Corporation as sponsor, and the authors include employees of Mitsubishi Tanabe Pharma Corporation, Mineralys Therapeutics, and ICON, the contract research organization that conducted the study.
Healthy male participants in the dose-escalation parts
“Oral administration of lorundrostat, either as single dose up to 800 mg under fasted conditions (SAD part 1) or as once‐daily dose up to 360 mg for 7 days under fed conditions (MAD part 2), was well tolerated with a favorable safety profile in a group of healthy male participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Duration of sodium depletion not addressed
“Although the urinary electrolyte measurements confirmed that there was a brief period of natriuresis at all doses tested, the duration and stability of the sodium depletion is not addressed by that measurement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Funding and author affiliations
“All studies reported in this manuscript were funded by Mineralys Therapeutics, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hidetoshi Shimizu, Yoshiyasu Ohta, Kei Ogawa, Sheikh Mohammed Ashfaq Rahman, Aya Fujii, Yuki Hiraga, Mizue Kawai, and Kanami Sugimoto‐Kawabata are employees of Mitsubishi Tanabe Pharma Corporation, which invented and out‐licensed the compound to Mineralys Therapeutics, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Michael A. Tortorici, Stephen Djedjos, and David M. Rodman are employees of Mineralys Therapeutics, Inc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote